Commissioner for Patents BOX PATENT APPLICATION U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

"Express Mail" Mailing Label Number	EL 833 312 780 US
Date of Deposit	November 27, 2001
I hereby certify that this transmittal letter and the papers deposited with the United States Postal Service "Express 1.10 on the date indicated above and is addressed to the APPLICATION, U.S. Patent and Trademark Office, P.O. Signature	Mail Post Office to Addressee" service under 37 CFR Commissioner for Patents, BOX PATENT
Ilidio P. Card	
Please Print Name of Pers	on Signing

Dear Sir:

Um. Am. 4""

###

Q1

7,

j=4

Transmitted herewith for filing is the Utility patent application of:

Inventor(s): Malcolm L. Gefter; David I. Israel; John L. Joyal; and Michael Gosselin

For: "Therapeutic Agents and Methods of Use Thereof For Treating an Amyloidogenic Disease"

Enclosed are:

- X 51 pages of Specification, 9 pages of Claims and 1 page of Abstract;
- X 12 sheets of Drawings (Figures 1- 12);
- X 5 pages of unexecuted Declaration, Petition and Power of Attorney;
- X Transmittal Letter for Diskette Containing Sequence Listing;
- X 6 pages of Sequence Listing (Paper Copy);
- X Diskette Containing Computer Readable Copy of the Sequence Listing;
- X 4 pages of Application Data Sheet;
- \times 1 page of Statement of Limited Recognition Under 37 C.F.R. §10.9(b) for Maria C. Laccotripe; and
- X Pre-paid Acknowledgment Postcard.
- X Applicant claims small entity status. See 37 C.F.R. 1.27.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col	. 2)
FOR:	NO. FILED	NO.	EXTRA
BASIC FEE	///////////////////////////////////////	///////	/////////
TOTAL CLAIMS	183 - 20	=	163
INDEP. CLAIMS	4 - 3	=	1
MULTIPLE DEPENDENT CLAIMS PRESENTED			

^{*} If the difference in Col. 2 is less than zero, enter "0" in Col. 2.

SMA	II	ENTITY

DIVIT KEL	CIVILI	
RATE	FEE	<u>OR</u>
////////	\$ 370	<u>OR</u>
x 9=	\$ 1467	OR
x 42	\$ 42	OR
+140	\$ 140	<u>OR</u>
TOTAL	\$2019.00	<u>OR</u>

OTHER THAN SMALL ENTITY

RATE	FEE
///////	\$
x 18=	\$
x 84	\$
+280	\$
TOTAL	0 -
	1

in a	
A. S.	
Jun 1860	
Ü	
There of the	
Taranta A	

SE.	
in the second	
**	
100	
Table Home	
Table Home	
Table Home	
100	

	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No		
		Any additional filing fees required under 37 C.F.R. 1.16. Any patent application processing fees under 37 C.F.R. 1.17.	
		numissioner is hereby authorized to charge payment of the following fees during the pendency of lication or credit any overpayment to Deposit Account No	
		Any patent application processing fees under 37 C.F.R. 1.17. The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R 1.311(b).	
		Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.	
X	Address address	all future communications to Giulio A. DeConti, Jr., Esq. at Customer No. 000959 whose is:	

Lahive & Cockfield, LLP 28 State Street Boston, Massachusetts 02109

Date: November 27, 2001

LAHIVE & COCKFIELD, LLP

Attorneys at Law

By: Maria C. Laccotripe, Ph.D., J.D.

Limited Recognition Under 37 C.F.R. §10.9(b)

Agent for Applicant 28 State Street Boston, MA 02109 Telephone (617) 227-7400 Facsimile (617) 742-4214

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Malcolm L. Gefter, et al.

Serial No.: filed herewith

Filed: November 27, 2001

For: THERAPEUTIC AGENTS AND METHODS

OF USE THEREOF FOR TREATING AN

AMYLOIDOGENIC DISEASE

Attorney Docket No.: PPI-105

Commissioner for Patents Box Sequence Washington, D.C. 20231 Group Art Unit: unknown

Examiner: unknown

TRANSMITTAL LETTER FOR DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the above-referenced patent application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the sequence listing appearing on pages 1- 6 of the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

"Express Mail" Mailing Label Number EL 833 312 780 US	Respectfully submitted,
Date of Deposit November 27, 2001 I hereby certify that this transmittal letter and the papers referred to as	Sacrotype
being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PATENT APPLICATION, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202 Signature Ilidio P. Cardoso Please Print Name of Person Signing	Maria C. Laccotripe, Ph.D., J.D. Limited Recognition Under 37 C.F.R. §10.9(b) Agent for Applicant LAHIVE & COCKFIELD, LLP 28 State Street Boston, MA 02109 (617) 227-7400

Date: November 27, 2001

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe's employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: September 4, 2002

Harry L. Moatz

Director of Enrollment and Discipline